0001567619-22-018291.txt : 20221005 0001567619-22-018291.hdr.sgml : 20221005 20221005214619 ACCESSION NUMBER: 0001567619-22-018291 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221003 FILED AS OF DATE: 20221005 DATE AS OF CHANGE: 20221005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ekman Lars CENTRAL INDEX KEY: 0001376117 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35676 FILM NUMBER: 221296980 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO CENTRAL INDEX KEY: 0001559053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 011-353-1-236-2500 MAIL ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: Prothena Corp plc DATE OF NAME CHANGE: 20121102 FORMER COMPANY: FORMER CONFORMED NAME: Neotope Corp Ltd DATE OF NAME CHANGE: 20120926 4 1 doc1.xml FORM 4 X0306 4 2022-10-03 0 0001559053 PROTHENA CORP PUBLIC LTD CO PRTA 0001376117 Ekman Lars C/O PROTHENA BIOSCIENCES INC 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 1 0 0 1 Chair of the Board Ordinary Shares, par value $0.01 per share 2022-10-03 4 M 0 15833 6.41 A 16076 D Ordinary Shares, par value $0.01 per share 2022-10-03 4 S 0 3508 60.3204 D 12568 D Ordinary Shares, par value $0.01 per share 2022-10-03 4 S 0 4277 61.0726 D 8291 D Ordinary Shares, par value $0.01 per share 2022-10-03 4 S 0 6355 62.1050 D 1936 D Ordinary Shares, par value $0.01 per share 2022-10-03 4 S 0 1693 62.9609 D 243 D Stock Option (right to buy) 6.41 2022-10-03 4 M 0 15833 0 D 2023-01-29 Ordinary Shares 15833 47501 D The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The transaction was executed in multiple trades in prices ranging from $59.60 to $60.59, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. The transaction was executed in multiple trades in prices ranging from $60.60 to $61.59, inclusive. The transaction was executed in multiple trades in prices ranging from $61.61 to $62.47, inclusive. The transaction was executed in multiple trades in prices ranging from $62.66 to $63.47, inclusive. The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. /s/ Michael J. Malecek, as attorney-in-fact for Lars G. Ekman 2022-10-05